Channels - Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study

Similar Items: Anifrolumab Plus Standard of Care Reduces Long‐Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real‐World External Control Study

Quick Look
Long‐Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus
Quick Look
A Diagnostic Pitfall: Lupus Mastitis Presenting Before Diagnosis of Systemic Lupus Erythematosus
Quick Look
Thymoma-Associated Systemic Lupus Erythematosus and Myasthenia Gravis
Quick Look
Anifrolumab in Refractory Dermatomyositis and Antisynthetase Syndrome
Quick Look
Italian Olfactory Identification Test in Systemic Lupus Erythematosus: Association of Olfactory Impairment With Chronic Damage and Anti–β2‐Glycoprotein I Antibodies
Quick Look
Albuminuria in Lupus Nephritis: the hidden threat to cardiovascular health
Quick Look
Concomitant Systemic Lupus Erythematosus and Glanzmann Thrombocytopenia: A Case Report and Literature Review
Quick Look
Duration of Belimumab Therapy and Timing of Initiation as Predictors of Clinical Outcomes in Childhood-Onset Systemic Lupus Erythematosus: A Real-World Retrospective Study
Quick Look
Lupus Enteritis Presenting as Acute Abdomen with Clear Gelatinous Stools in a Woman with Systemic Lupus Erythematosus: A Case Report and Literature Review
Quick Look
Bilateral eyelid erythema and oedema accompanied by systemic lupus erythematosus and syndrome of inappropriate antidiuretic hormone secretion
Quick Look
Reproducible Molecular Subtypes in Systemic Lupus Erythematosus Are Associated With Disease Activity, Serology, and Distinct Trajectories Over Time
Quick Look
Case Report: Secukinumab Experience in a Patient With Coexistence of Systemic Lupus Erythematosus, Ankylosing Spondylitis, and Antiphospholipid Antibody Syndrome
Quick Look
Prospective Quantification of Glucocorticoid Toxicity Across Dosage Ranges in Systemic Lupus Erythematosus: Insights from the Glucocorticoid Toxicity Index
Quick Look
Longitudinal Trajectories and Predictors of Health-Related Quality of Life in Systemic Lupus Erythematosus: A 2-Year Longitudinal Cohort Study
Quick Look
Novel use of anifrolumab in a young patient with Jo-1-positive juvenile dermatomyositis
Quick Look
From Nerve to Autoimmunity: Acute Guillain-Barré Syndrome in a 4-Year-Old with Early-Onset Pediatric Systemic Lupus Erythematosus
Quick Look
Guillain-Barré Syndrome, Subtype AMAN, Can Only Be Attributed to Lupus Erythematosus if All Infectious Causes Have Been Ruled Out [Letter]
Quick Look
Guillain-Barré Syndrome, Subtype AMAN, Can Only Be Attributed to Lupus Erythematosus if All Infectious Causes Have Been Ruled Out [Response to Letter]
Quick Look
Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity
Quick Look
A Review and Future Perspective on Renal Outcome Definitions in Lupus Nephritis
Quick Look
Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis
Quick Look
A Case of Hydralazine-Induced ANCA Vasculitis/Lupus Overlap Syndrome Presenting as Persistent Bicytopenia
Quick Look
Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation
Quick Look
Corrigendum “immune cell alterations in a pristane‐induced lupus model in C57BL/6J mice”